Cefpodoxime proxetil
Cefpodoxime proxetil is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Upper respiratory tract infections including acute otitis media, pharyngitis, tonsillitis, acute exacerbation of chronic bronchitis (AECB), and acute maxillary sinusitis
- Acute uncomplicated urethral and cervical gonorrhea and ano-rectal gonorrhea (females) caused by N. gonorrhoeae (no longer recommended by CDC) [3]
- Uncomplicated skin and skin-structure infections S. aureus (MSSA) or S. pyogenes.
- Uncomplicated urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilis, or S. saprophyticus.
- Community-acquired pneumonia (CAP) caused by S. pneumoniae or H. influenzae
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
- Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
- IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first[1].
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Upper respiratory tract infections including acute otitis media, pharyngitis, tonsillitis, acute exacerbation of chronic bronchitis (AECB), and acute maxillary sinusitis
- Acute uncomplicated urethral and cervical gonorrhea and ano-rectal gonorrhea (females) caused by N. gonorrhoeae (no longer recommended by CDC) [3]
- Uncomplicated skin and skin-structure infections S. aureus (MSSA) or S. pyogenes.
- Uncomplicated urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilis, or S. saprophyticus.
- Community-acquired pneumonia (CAP) caused by S. pneumoniae or H. influenzae
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
- Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
- IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first[1].
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2022 Unbound Medicine, Inc. All rights reserved